Table 3.

COVID-19 outcomes by outpatient SARS-CoV-2 treatment among SARD patients (n=704).

Outcome	All SARD patients with COVID-19 (n=704)	Any outpatient treatment (n=426)*	Nirmatrelvir/ritonavir use (n=307)	Monoclonal antibody use (n=105)	No outpatient treatment (n=278)
Hospitalization	58 (8.2%)	9 (2.1%)	4 (1.3%)	5 (4.8%)	49 (17.6%)
Death	3 (0.4%)	1 (0.2%)	1 (0.3%)	0 (0.0%)	2 (0.7%)
Severe COVID-19 (hospitalization or death)	58 (8.2%)	9 (2.1%)	4 (1.3%)	5 (4.8%)	49 (17.6%)
Rebound	N/A	N/A	25/311** (8.0%)	N/A	N/A

^*There were no severe COVID-19 outcomes among molnupiravir (n=5), remdesivir (n=3), or combination (n=6; 4 received nirmatrelvir/ritonavir and monoclonal antibodies and 2 received molnupiravir and monoclonal antibodies) users.

^**The denominator for COVID-19 rebound also includes 4 patients who used nimatrelvir/ritonavir as a combination with monoclonal antibodies. There was also 1 COVID-19 rebound case among 7 molnupiravir users (14.3%).

COVID-19, coronavirus disease 2019; N/A, not applicable; SARD, systemic autoimmune rheumatic disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.